These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1043 related items for PubMed ID: 16946130

  • 1. Cholesteryl ester transfer protein decreases high-density lipoprotein and severely aggravates atherosclerosis in APOE*3-Leiden mice.
    Westerterp M, van der Hoogt CC, de Haan W, Offerman EH, Dallinga-Thie GM, Jukema JW, Havekes LM, Rensen PC.
    Arterioscler Thromb Vasc Biol; 2006 Nov; 26(11):2552-9. PubMed ID: 16946130
    [Abstract] [Full Text] [Related]

  • 2. Cholesteryl ester transfer protein (CETP) expression protects against diet induced atherosclerosis in SR-BI deficient mice.
    Harder C, Lau P, Meng A, Whitman SC, McPherson R.
    Arterioscler Thromb Vasc Biol; 2007 Apr; 27(4):858-64. PubMed ID: 17272756
    [Abstract] [Full Text] [Related]

  • 3. Restoration of high-density lipoprotein levels by cholesteryl ester transfer protein expression in scavenger receptor class B type I (SR-BI) knockout mice does not normalize pathologies associated with SR-BI deficiency.
    Hildebrand RB, Lammers B, Meurs I, Korporaal SJ, De Haan W, Zhao Y, Kruijt JK, Praticò D, Schimmel AW, Holleboom AG, Hoekstra M, Kuivenhoven JA, Van Berkel TJ, Rensen PC, Van Eck M.
    Arterioscler Thromb Vasc Biol; 2010 Jul; 30(7):1439-45. PubMed ID: 20431066
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Thyroid hormone increases plasma cholesteryl ester transfer protein activity and plasma high-density lipoprotein removal rate in transgenic mice.
    Berti JA, Amaral ME, Boschero AC, Nunes VS, Harada LM, Castilho LN, Oliveira HC.
    Metabolism; 2001 May; 50(5):530-6. PubMed ID: 11319713
    [Abstract] [Full Text] [Related]

  • 6. Severe atherosclerosis in transgenic mice expressing simian cholesteryl ester transfer protein.
    Marotti KR, Castle CK, Boyle TP, Lin AH, Murray RW, Melchior GW.
    Nature; 1993 Jul 01; 364(6432):73-5. PubMed ID: 8316302
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Cholesteryl ester transfer protein directly mediates selective uptake of high density lipoprotein cholesteryl esters by the liver.
    Gauthier A, Lau P, Zha X, Milne R, McPherson R.
    Arterioscler Thromb Vasc Biol; 2005 Oct 01; 25(10):2177-84. PubMed ID: 16123327
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Bexarotene induces dyslipidemia by increased very low-density lipoprotein production and cholesteryl ester transfer protein-mediated reduction of high-density lipoprotein.
    de Vries-van der Weij J, de Haan W, Hu L, Kuif M, Oei HL, van der Hoorn JW, Havekes LM, Princen HM, Romijn JA, Smit JW, Rensen PC.
    Endocrinology; 2009 May 01; 150(5):2368-75. PubMed ID: 19147676
    [Abstract] [Full Text] [Related]

  • 11. Effect of CETP on the plasma lipoprotein profile in four strains of transgenic mouse.
    Takahashi H, Takahashi A, Maki M, Sasai H, Kamada M.
    Biochem Biophys Res Commun; 2001 Apr 27; 283(1):118-23. PubMed ID: 11322777
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. A low-saturated-fat, low-cholesterol diet decreases plasma CETP activity and pre beta-HDL formation but does not affect cellular cholesterol efflux to plasma from type 1 diabetic patients.
    De Vries R, Beusekamp BJ, Kerstens MN, Groen AK, Van Tol A, Dullaart RP.
    Scand J Clin Lab Invest; 2005 Apr 27; 65(8):729-37. PubMed ID: 16319046
    [Abstract] [Full Text] [Related]

  • 15. Cholesteryl ester transfer protein (CETP) inhibition beyond raising high-density lipoprotein cholesterol levels: pathways by which modulation of CETP activity may alter atherogenesis.
    Klerkx AH, El Harchaoui K, van der Steeg WA, Boekholdt SM, Stroes ES, Kastelein JJ, Kuivenhoven JA.
    Arterioscler Thromb Vasc Biol; 2006 Apr 27; 26(4):706-15. PubMed ID: 16439711
    [Abstract] [Full Text] [Related]

  • 16. Apolipoprotein CI overexpression is not a relevant strategy to block cholesteryl ester transfer protein (CETP) activity in CETP transgenic mice.
    Gautier T, Masson D, Jong MC, Pais de Barros JP, Duverneuil L, Le Guern N, Deckert V, Dumont L, Bataille A, Zak Z, Jiang XC, Havekes LM, Lagrost L.
    Biochem J; 2005 Jan 01; 385(Pt 1):189-95. PubMed ID: 15339254
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib.
    Clark RW, Sutfin TA, Ruggeri RB, Willauer AT, Sugarman ED, Magnus-Aryitey G, Cosgrove PG, Sand TM, Wester RT, Williams JA, Perlman ME, Bamberger MJ.
    Arterioscler Thromb Vasc Biol; 2004 Mar 01; 24(3):490-7. PubMed ID: 14739125
    [Abstract] [Full Text] [Related]

  • 19. Torcetrapib does not reduce atherosclerosis beyond atorvastatin and induces more proinflammatory lesions than atorvastatin.
    de Haan W, de Vries-van der Weij J, van der Hoorn JW, Gautier T, van der Hoogt CC, Westerterp M, Romijn JA, Jukema JW, Havekes LM, Princen HM, Rensen PC.
    Circulation; 2008 May 13; 117(19):2515-22. PubMed ID: 18458167
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 53.